Jiuzhou Pharmaceutical(SH:603456) Xin Lang Cai Jing·2025-11-21 01:25Core Insights - On November 20, Jiuzhou Pharmaceutical experienced a decline of 2.09% with a trading volume of 487 million yuan, indicating market volatility [1] - The company reported a financing buy-in of 65.75 million yuan and a net financing buy of 6.15 million yuan on the same day, reflecting investor interest despite the stock price drop [1] - As of September 30, Jiuzhou Pharmaceutical achieved a revenue of 4.16 billion yuan, marking a year-on-year growth of 4.92%, and a net profit of 748 million yuan, which is an 18.51% increase compared to the previous year [2] Financing and Trading Activity - Jiuzhou Pharmaceutical's financing balance reached 620 million yuan, accounting for 3.52% of its market capitalization, indicating a high level of leverage [1] - The company’s margin trading showed a low short-selling balance of 2.68 million yuan, suggesting limited bearish sentiment among investors [1] - The stock's financing balance is above the 90th percentile of the past year, indicating a high level of investor engagement [1] Shareholder and Dividend Information - As of September 30, the number of Jiuzhou Pharmaceutical shareholders increased by 10.22% to 59,200, while the average number of circulating shares per shareholder decreased by 9.27% [2] - The company has distributed a total of 2.183 billion yuan in dividends since its A-share listing, with 1.245 billion yuan distributed over the last three years [3] - Major institutional shareholders include Hong Kong Central Clearing Limited and China Europe Medical Health Mixed A, with both increasing their holdings [3]